---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015338"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:40:13.978567+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18

## Summary
- Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
- Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.
- Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.
- Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.
- CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged.

## SEC filing metadata
- accession: 0001641172-25-015338
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015338
- JSON: https://secwatch.observer/filing/0001641172-25-015338.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015338.txt

## Key facts
- Governance Changes
  Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).
  - Change: charter amendment
  - Effective: 2025-06-13
  source text: In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm
- Governance Changes
  Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).
  - Change: bylaw amendment
  - Effective: 2025-06-13
  source text: Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.